VivaGel condom receives regulatory approval in Europe
Filed with ASX · · 2 pages · English
Starpharma Holdings Limited on 6ix
In the deck
Story so far
Earlier from Starpharma
- UK launch of VivaGel BV
- DEP outperforms Gemzar in human pancreatic cancer model
- FDA Authorises Clinical Trial with AstraZeneca DEP product
- DEP irinotecan synergistic with Lynparza in refractory model
- VivaGel BV regulatory approvals continue in Asia
Later from Starpharma
- AGM - Chairman address and CEO presentation
- DEP cabazitaxel progresses to phase 2 on positive results
- Starpharma receives $4.9M R&D tax incentive refund
- Commencement of phase 1 trial for AZD0466 utilising DEP
- Quarterly Cashflow Report
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma